Institute for Complex Molecular Systems gets new accommodation in an architecturally and historically special building

04-10-2012

The Institute for Complex Molecular Systems (ICMS) at Eindhoven University of Technology (TU/e) opens its new facility. The university has transformed its former boilerhouse dating back to 1959 into an architecturally special building for a special user: ICMS. Named the Ceres building, this ...

more

27-09-2012

Bioceros BV announced that it participates in the ACCESS project consortium led by Synthon, which has been awarded a grant within the GO EFRO program. The budget of almost €1 million is available for the development of improved antibody manufacturing systems. Other partners in this consortium ...

more

18-09-2012

Mucosis B.V. announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately. Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.Mr. Johnston ...

more

13-09-2012

The whitefly is a major problem for open field tomato cultivation throughout the world. Scientists of Wageningen UR together with a number of partners have discovered genes for resistance to the whitefly in a wild relative of the common tomato. The scientists hope that resistant varieties can ...

more

05-09-2012

to-BBB has been awarded funding of EUR 1.25 million by the European Commission’s 7th Framework Programme as part of a EUR 5 million consortium project for the preclinical development of novel treatments for inherited retinal degenerative diseases. The consortium additionally consists of ...

more

14-08-2012

In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. The discovery, published in the journal Science, addresses a ...

more

20-07-2012

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year ...

more

New research approach can help predict the ‘tenability’ of antibiotics

05-07-2012

Research by Wageningen University, part of Wageningen UR, has shown that the development of bacteria with resistance against the antibiotic cefotaxime occurs more often and more predictably than was previously assumed. Bacterial populations were found to have many mutations that increase ...

more

02-07-2012

Plant Research International, part of Wageningen UR, has used its next generation sequencing DNA equipment to show that it is the Lettuce big vein associated virus (LBVaV) itself that causes necrotic symptoms in lettuce. For years it was assumed that the virus was present in lettuce without ...

more

27-06-2012

Prosensa has won the Emerging Star accolade at the European Mediscience Awards. The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognising achievements in the life sciences industry. ...

more